Inclusion Criteria : 
  -  CAC score > 10 
  -  Framingham risk score ( 10 % or above ) 
  -  Subjects are required to be on stable concomitant medications for at least 12 weeks prior to randomization
  -  Subjects with diabetic must have HbA1C < 8.0 , and stable HbA1C level variation range within 0.5 % for three months. 
Exclusion Criteria : 
  -  Hypersensitivity to AGE therapy , 
  -  Unstable medical , psychiatric , or substance abuse disorder that may interfere with continuation in the study , 
  -  Weight â‰¥ 325 pounds , 
  -  Bleeding disorder , 
  -  History of myocardial infarction , 
  -  Stroke
  -  Life - threatening arrhythmia within prior 6 months , 
  -  Resting hypotension ( systolic < 90 mmHg ) or hypertension ( resting blood pressure > 170 / 110 ) 
  -  Heart failure NYHA class III or IV , 
  -  History of malignancy within the last 5 years ( other than skin cancer ) or evidence of active cancer which would require concomitant cancer chemotherapy
  -  Serum creatinine > 1.4 mg / dl
  -  Triglycerides > 400 at baseline visit
  -  Diabetic subjects with HbA1C > 8 % , 
  -  Drug or alcohol abuse
  -  Conditions interfering with accurate assessment of coronary calcification ( metal clips , bypass patients , intracoronary stents ) and drug absorption ( partial ileal bypass or malabsorption syndrome ) . 
  -  Current use of anticoagulants ( except for antiplatelet agents ) 
  -  Chronic renal failure
  -  Liver failure
  -  Hematological or biochemical values at baseline visit outside the reference ranges considered as clinically significant.